Nuveen Asset Management LLC Sells 127,530 Shares of Evolus, Inc. (NASDAQ:EOLS)

Nuveen Asset Management LLC cut its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 14.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 769,576 shares of the company's stock after selling 127,530 shares during the quarter. Nuveen Asset Management LLC owned approximately 1.22% of Evolus worth $8,496,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Evolus by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company's stock worth $347,000 after acquiring an additional 1,094 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after acquiring an additional 1,291 shares during the period. Rhumbline Advisers raised its position in Evolus by 2.2% in the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock worth $885,000 after acquiring an additional 1,762 shares during the period. Tradition Wealth Management LLC raised its position in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after acquiring an additional 2,000 shares during the period. Finally, MetLife Investment Management LLC raised its position in Evolus by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock worth $378,000 after acquiring an additional 2,044 shares during the period. Institutional investors own 90.69% of the company's stock.

Evolus Stock Performance

Shares of NASDAQ EOLS traded up $0.78 during midday trading on Monday, hitting $9.97. The company's stock had a trading volume of 1,797,155 shares, compared to its average volume of 719,553. The stock has a fifty day moving average price of $10.56 and a 200 day moving average price of $11.96. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $642.83 million, a price-to-earnings ratio of -10.96 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. BTIG Research began coverage on shares of Evolus in a research report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, April 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus currently has an average rating of "Buy" and a consensus price target of $23.75.

Insider Activity

In related news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.36. Following the sale, the chief marketing officer now owns 95,671 shares of the company's stock, valued at approximately $1,268,597.46. This represents a 4.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Moatazedi sold 6,251 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the sale, the insider now directly owns 508,619 shares in the company, valued at $6,306,875.60. This trade represents a 1.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 86,241 shares of company stock valued at $1,048,666 over the last quarter. Company insiders own 5.90% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.